Navigation Links
Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Date:10/15/2007

AMSTERDAM, October 15 /PRNewswire/ -- Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced today that it has acquired the rights to the discovery of a major mechanism of resistance to the frequently-used breast cancer drug Herceptin(R), which is published in the October 15 issue of the journal "Cancer Cell".

The antibody drug Herceptin(R) targets the HER2 protein, which is hyper-active in about one in four breast cancers and the HER2 protein contributes to aggressive cancer behavior. Striking initial responses are observed in combination with chemotherapy in more than half of treated patients. However, the majority of responding patients eventually develop resistance to Herceptin-based therapies. The laboratory of Agendia's Chief Scientific Officer, Prof. Rene Bernards, today published a rapid method to identify biomarkers associated with non-responsiveness to cancer drugs in cell culture and used the technology to identify a mechanism of resistance to Herceptin-based cancer therapy. His work also demonstrated that these biomarkers indeed have predictive value in patients treated with this drug, thus validating the approach.

"The availability of biomarkers that predict responses to cancer therapy is instrumental to the rational use of cancer drugs in the clinic. Elucidating the molecular mechanism of drug resistance can be critical to identify patients that fail to respond to therapy and may help design more efficient treatment protocols", says Rene Bernards. "Although more work is needed to further validate our findings, the method is generally applicable to find mechanisms of drug resistance and should expedite the development of biomarkers that are associated with therapy non-responsiveness".

The technology used relies on the simultaneous inactivation of thousands of genes through a process known as RNA interference in cells that are sensitive to a specific cancer drug. If the inactivation of a specific gene confers resistance to a cancer drug, cells harboring the inactivated gene can continue to grow in the presence of the cancer drug and can be readily identified. In the present study deregulation of the phosphatidylinositol 3-kinase pathway, which is mutated in up to half of all breast cancer tumors, was identified as a major mechanism of unresponsiveness to Herceptin-based therapies.

"We are very excited by these findings and pleased that we have been able to secure the rights", comments Agendia's CEO, Dr. Bernhard Sixt. "It is likely that a similar mechanism contributes to unresponsiveness to other cancer therapeutics that target the EGF receptor in colon and lung cancer". Agendia will develop a microarray-based diagnostic to identify this drug resistance mechanism.

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to receive FDA approval for it's breast cancer test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)(*), is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

(*) CupPrint(R) is based on a license to the TUA database of AviaraDx


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Fiserv acquires crime management software firm
2. GenTel acquires GlaxoSmithKline chip platform
3. Tushaus Computer acquires managed service business
4. RedPrairie acquires Denver software company
5. Eagle Technology acquires some synergy
6. Brady Corp. acquires Korean counterpart
7. Canadian firm acquires Silicon Logic
8. Imago acquires synergistic British firm
9. Fiserv acquires insurance, training product lines
10. Amazon acquires Madison-based Shopbop
11. Metavante acquires health-care payments firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):